Pinion Immunotherapeutics Publishes Preclinical Data Supporting Clinical-Ready RNA Immunotherapy for HPV-16 Cervical Precancer
NORTH BETHESDA, Md. -- Pinion Immunotherapeutics has published preclinical data supporting ARV-2001, its lead RNA immunotherapy, in the peer-reviewed journal Vaccines .
With an Investigational New Drug application cleared by the FDA, Pinion is ready to begin clinical development for women with HPV-16-positive high-grade cervical precancer (CIN2/3).
Read More
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.